Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Dose Escalation + Cohort Expansion Phase 1 Trial on Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 in Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

NCT06088888 is registered in ClinicalTrials.gov with Shenzhen TargetRx Co., Ltd. as lead sponsor.

NCT NCT06088888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06088888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Dose Escalation + Cohort Expansion Phase 1 Trial on Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 in Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Lead sponsor
Shenzhen TargetRx Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
July 2, 2024
Completion date
June 30, 2027
Enrollment
90 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia